The preliminary efficacy of interferon-α and ribavirin combination treatment of chronic hepatitis C in HIV-infected patients

Chinese Medical Journal

Volumn 118, Issue 14, 2005, Pages 1195-1200

  Zheng, Yu Huang ^a   Zhang, Chun Ying ^a   He, Yan ^a   Zhou, Hua Ying ^a   Zou, Wen ^a   Ding, Pei Pei ^a   Huang, Li ^a   Li, Hui ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Hepatitis C virus; Human immunodeficiency virus; Inteferon; Ribavirin

Indexed keywords

ALPHA2B INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; RIBAVIRIN; VIRUS RNA;

ADULT; ANEMIA; ANOREXIA; ARTICLE; AUTOIMMUNE DISEASE; BLOOD CELL COUNT; CHINESE; CHRONIC DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOLOGIC DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER FUNCTION; LYMPHOCYTE COUNT; MALE; MENTAL DISEASE; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; T LYMPHOCYTE; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL;

EID: 22944450031     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Wu N, Li D, Zhu B, et al. Preliminary research on the co-infection of human immunodeficiency virus and hepatitis virus in intravenous drug users. Chin Med J 2003;116:1318-1320.
2. Tossing G. Management of chronic hepatitis C in HIV-co-infected patients - results from the First International Workshop on HIV and Hepatitis co-infection. Eur J Med Res 2005;10:43-45.
3. Carlos MJ, Gastilla J, Lopez M, et al. Impact of chronic hepatitis C on HIV-1 disease progression. HIV Clin Trials 2004;5:125-131.
4. Rodriguez B, Bobak DA. Management of hepatitis C in HIV-infected patients. Curr Infect Dis Rep 2005;7:91-102.
5. Vencent S, Massimo P, Mark S, et al. Care of patient's hepatitis C and HIV co-infection. AIDS 2004; 18:1-12.
6. Rochstroh JK, Spengler V. HIV and hepatitis C virus co-infection. Lancet Infect Dis 2004;4:437-444.
7. Mauss S. Viral hepatitis B/C and HIV. Therapy of double infections. MMW Fortschr Med (German) 2003;145:21-25.
8. Jia H, Du J, Zhu S, et al. Clinical observation of serum IL-18, IL-10 and sIL-2R levels in patients with chronic hepatitis C pre- and post antiviral treatment. Chin Med J 2003;116:605-608.
9. Huber M, Weber R, Oppliger R, et al. Interferon alpha-2a plus ribavirin 1000/1200 mg versus Interferon alpha-2a plus ribavirin 600 mg for chronic hepatitis C infection in patients on opiate maintenance treatment: an open-label randomized multicenter trial. Infection 2005;33:25-29.
10. Perez-Olmeda M, Soriano V, Asensi V, et al. Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha-2b plus ribavirin. AIDS Res Hum Retroviruses 2003;19:1083-1099.
11. Board of Infectious Diseases and Parasitosis of Chinese Medical Association. The Protocol for Preventing and Treating Viral Hepatitis. Chin J Infect Dis (Chin) 2001; 19:56-61.
12. Xu LZ. Guideline for Preventing and Treating AIDS (Chin). Tianjin: Tianjin Science and Technology Press; 2000:346-368.
13. Sherman K, Roustrer S, Chung R, et al. Hepatitis C prevalence in HIV-infected patients across sectional analysis of the US ACTG. Antririr Ther 2000;5(Suppl 1):64-65.
14. Sulkowk MS, Mast EE, Seeff LB, et al. Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis 2000;30:S77-S84.
15. Hagan H, Thiede H. Sharing of drug preparation equipment as a risk factor of hepatitis C. Am J Public Health 2001;91:42-46.
16. Kottilil S, Polis MA, Kovacs JA. HIV infection, hepatitis C infection and HAART: hard clinical choices. JAMA 2004;292:243-250.
17. Ballesteros AL, Miro O, Lopez S, et al. Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both. Antivir Ther 2004;9:969-977.
18. Neau D, Trimoulet P, Winnock M, et al. Comparison of 2 regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients. Clin Infect Dis 2003;36:1564-1571.
19. Board of Liver Diseases of Chinese Medical Association. Guideline for Preventing and Treating Viral Hepatitis C. Chin J Infect Dis (Chin) 2004;22:131-136.
20. Jablonowski H. IFN-alpha: therapeutic options in HIV and HIV/HCV dual infection. Infection 2003;31:131-133.
21. Emilie D, Burgard M, Lascoux-Combe C, et al. Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study. AIDS 2001;15:1435-1437.
22. Hatzakis A, Gargalianos P, Kiosses V, et al. Low-dose IFN-alpha monotherapy in treatment-naive individuals with HIV-1 infection: evidence of potent suppression of viral replication. J Interferon Cytokine Res 2001;21:861-869.
23. Talal AH, Shata MT, Markatou M, et al. Virus dynamics and immune responses during treatment in patients coinfected with hepatitis C and HIV. J Acquir Immune Defic Syndr 2004;35:103-113.
24. Mauss S, Valenti W, DePamphilis J, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004;18:F21-F25.
25. Husa P, Snopkova S, Chalupa P. Initial experience with treatment of chronic hepatitis C in HIV-positive patients (Czech). Vnitr Lek 2003;49:576-579.
26. Laguno M, Blanch J, Murillas J, et al. Depressive symptoms after initiation of interferon therapy in human immunodeficiency virus-infected patients with chronic hepatitis C. Antivir Ther 2004;9:905-909.
27. Zhou HY, Zheng YH, Yang X, et al. A twenty four week clinical trial using didonosine, stavudine and nevirapine for highly active antiretroviral therapy. J Chin Phys (Chin) 2003;5:1592-1595.
28. Glesby MJ, Bassett R, Alston-Smith B, et al. Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection. J Infect Dis 2005;191:686-693.
29. Alatrakchi N, Di Martino V, Thibault V, et al. Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIV-hepatitis C virus co-infection. AIDS 2004;18:121-123.
30. Romero M, Perez-Olmeda M. Garcia-Samaniego J, et al. Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations. Drug Saf 2004;27:7-24.
31. Puoti M, Zanini B, Quinzan GP, et al. A randomized, controlled trial of triple antiviral therapy as initial treatment of chronic hepatitis C in HIV-infected patients. J Hepatol 2004;41:312-318.
32. Fabris P, Barnes E, Tositti G, et al. Therapy of chronic hepatitis C virus infection in HIV co-infected people. Curr Pharm Des 2004;10:2111-2122.